2455
0
Loading version...
🔄 Update App
🔍 Check for Updates
Test Notification
🔔 Enable Notifications
📰 Fetch NHK News
🚀 Fetch TechCrunch News
🧪 Experiment
📰 Article Management
📚 Reading List
🎤 Speaking List
📊 Statistics
💻 Software Statistics
Push Admin
Edit Reading
Back to List
Basic Information
Title
Please enter a title.
URL
Please enter a valid URL.
Date
カテゴリID
画像ファイル名
統計情報
単語数:
129語
読了回数:
0回
作成日:
2023/08/21 07:12
更新日:
2025/12/09 00:53
本文
本文
An expert panel at Japan's health ministry will convene on Monday to decide whether to approve a new Alzheimer's drug. It is the first drug to target a specific cause of the disease. Approval would allow the domestic production and sale of lecanemab, which was jointly developed by Japanese firm Eisai and its US partner Biogen. The drug is the first-ever treatment designed to slow the progression of the disease by reducing the accumulation of amyloid beta protein in the brain. Eisai applied for the ministry's approval in January. The company says its large global clinical study shows that the treatment cut cognitive and functional decline by 27 percent after 18 months compared with a placebo group. The US Food and Drug Administration fully approved the drug in July.
本文を入力してください。
メモ
メモ・感想
キャンセル
更新
Debug Info:
Saved State:
-
Redirected Flag:
-
Current URL:
-
Refresh
Close
Debug
Send Report
Send Report
Draw Arrow
Clear
Message:
Cancel
Send
